Article Information
History
- December 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Marta Bertran1,
- Nick Andrews1,
- Chloe Davison1,
- Bennet Dugbazah1,
- Jacob Boateng1,
- Rachel Lunt1,
- Jo Hardstaff2,
- Melanie Green2,
- Paula Blomquist2,
- Charlie Turner2,
- Hamish Mohammed3,4,
- Rebecca Cordery1,
- Sema Mandal1,
- Colin Campbell1,
- Shamez N Ladhani1,5,
- Mary Ramsay1,
- Gayatri Amirthalingam1 and
- Jamie Lopez Bernal1,*
- 1Immunisations and Vaccine Preventable Diseases Division, UK Health Security Agency
- 2Monkeypox Data, Epidemiology and Analytics Cell, UK Health Security Agency, United Kingdom
- 3Division of Blood Safety, Hepatitis, STIs and HIV, UK Health Security Agency, United Kingdom
- 4Institute for Global Health, University College London, United Kingdom
- 5Paediatric Infectious Diseases Research Group, St. George’s University of London, Cranmer Terrace, London SW17 0RE, United Kingdom
- ↵* Corresponding author; email: jamie.lopezbernal2{at}ukhsa.gov.uk
Posted December 14, 2022.
Effectiveness of one dose of MVA-BN smallpox vaccine against monkeypox in England using the case-coverage method
